13
Participants
Start Date
January 31, 2009
Primary Completion Date
February 28, 2013
Study Completion Date
July 31, 2015
GAA/TT-peptide vaccine and poly-ICLC
Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
GAA/TT-peptide vaccine and poly-ICLC
Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
University of Pittsburgh Cancer Institute, Pittsburgh
Comprehensive Cancer Center of Wake Forest University, Winston-Salem
Collaborators (1)
Oncovir, Inc.
INDUSTRY
National Cancer Institute (NCI)
NIH
Ian F. Pollack, M.D.
OTHER